{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"MTD was determined by testing increasing doses up to 20 mg/kg once daily dose escalation cohorts 1 to 3 with 3 patients each. MTD reflects highest dose of drug that did not cause an unacceptable side effect (dose limiting toxicity \\[DLT\\]) in more than 30% of patients; e.g., hematologic toxicities like Common Toxicity Criteria for Adverse Events (CTCAE) Grade 4 neutropenia in specific conditions, platelets \\< 10,000 cells/mm\\^3 that do not recover to 25,000 cells/mm\\^3; and specific non-hematologic/biochemical toxicities CTCAE Grade 3 or 4 (except fatigue and Grade 3 infections); CTCAE version 3.0 were used.","groups":[{"description":"Elotuzumab (5, 10, or 20 mg/kg) administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG000","title":"Phase 1 Elotuzumab + Lenalidomide and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"All participants in the safety population (all randomized participants who received at least 1 dose of study drug) in the escalation cohorts (Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone \\[Phase 1\\]; Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone \\[Phase 1\\]; and Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone \\[Phase 1\\]).","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Maximum Tolerated Dose (MTD) of Elotuzumab in Combination With Lenalidomide and Dexamethasone (Phase 1)","type":"PRIMARY","unitOfMeasure":"mg/kg"}